3-iodobenzylguanidine
3-iodobenzylguanidine Uses, Dosage, Side Effects, Food Interaction and all others data.
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
AdreView is a diagnostic radiopharmaceutical which contains a small quantity of iobenguane that is not expected to produce a pharmacodynamic effect. Patients with renal insufficiency may experience increased radiation exposure and impaired imaging results.
Trade Name | 3-iodobenzylguanidine |
Availability | Prescription only |
Generic | Iobenguane |
Iobenguane Other Names | 3-iodobenzylguanidine, m-iodobenzylguanidine, Metaiodobenzylguanidine, mIBG |
Related Drugs | glucagon, mannitol, Tubersol, arginine, inulin |
Type | |
Formula | C8H10IN3 |
Weight | Average: 275.0896 Monoisotopic: 274.991940755 |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
3-iodobenzylguanidine is a radiopharmaceutical agent used for the diagnosis of primary and metastatic pheochromocytoma or neuroblastoma.
Detection of primary and metastatic pheochromocytoma or neuroblastoma
3-iodobenzylguanidine is also used to associated treatment for these conditions: Metastatic Pheochromocytoma, Metastatic Neuroblastoma, Primary Neuroblastomas, Primary Pheochromocytomas, Unresectable, locally advanced iobenguane-scan positive Paraganglioma, Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas, Unresectable, metastatic iobenguane-scan positive Paraganglioma, Unresectable, metastatic iobenguane-scan positive Pheochromocytomas
How 3-iodobenzylguanidine works
Structure of iobenguane is similar to noradrenaline so it can be taken up by adrenergic tissue in the adrenal medulla, liver, heart, and spleen. Once taken up by noradrenaline transporters in the adrenergic nerve terminals, it is stored in the presynaptic storage vesicles. The radioactive iodine component is responsible for its imaging properties.
Toxicity
Oral mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50=980 mg/kg. The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.
Food Interaction
No interactions found.3-iodobenzylguanidine Hypertension interaction
[Moderate] 3-iodobenzylguanidine I-123 may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension.
It is recommended to assess the patient's pulse and blood pressure before and intermittently for 30 minutes after iobenguane I-123 administration.
Care should be exercised when using this agent in patients with hypertension.
Prior to 3-iodobenzylguanidine I-123 administration, ensure emergency cardiac and anti-hypertensive treatments are readily available.
3-iodobenzylguanidine Disease Interaction
Moderate: hypertension, parkinson's disease, renal impairment
Elimination Route
3-iodobenzylguanidine rapidly clears from the blood and is highly retained in adrenergic tissues.
Half Life
Physical half life = 13.2 hours
Elimination Route
Renally excreted unchanged (70%-90%) via glomerular filtration; Fecal (<1%)
Innovators Monograph
You find simplified version here 3-iodobenzylguanidine